Clinical trials: Difficile
Frail Elderly, Clostridioides Difficile
Clostridioides Difficile and Frailty
CDI is a major cause of antibiotics-associated diarrhoea. More than half of the patients affected are 70 years or older and frail. Mortality among older patients with CDI is high.
- Conditions
- Frail Elderly, Clostridioides Difficile, Geriatric Assessment, Faecal Microbiota Transplantation
- Trial name
- CLODIFRAIL (NCT05447533)
- Testing
- Comprehensive geriatric assessment (CGA), Continued geriatric care, Faecal microbiota transplantation (FMT)
- Where
- Denmark
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Clostridium Difficile Colitis
Small Bowel Transit Time in Clostridium Difficile Colitis
Clostridium difficile is a bacteria that can infect the colon and cause severe diarrhea in patients after recent antibiotic use. The current standard of care treatment for severe C. diff.
- Trial name
- NCT01309750
- Testing
- Small Bowel Transit Study
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Corewell Health East
Clostridium Difficile Infection
Fecal Microbiota Transplant
The study will provide data to show the effectiveness of Fecal Microbiota Transplant in patients with recurrent Clostridium difficile infection.
- Trial name
- NCT04090346
- Testing
- Fecal Microbiota Transplant
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Methodist Health System
Diarrhea
OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)
The purpose of this study is to investigate the safety and perform preliminary clinical evaluation in patients with mild to moderate CDAD.
- Trial name
- NCT00097422
- Testing
- OPT-80
- Where
- United States
- Sponsor
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Clostridium Difficile Infections
Virus as Treatment of C. Difficile Infection (VISION)
Fecal Virome Transplantation (FVT) has in small studies shown benefit in the treatment of recurrent C. difficile infection. In the VISION study we will treat patients with recurrent C.
- Trial name
- VISION (NCT06398379)
- Testing
- Fecal Virome Transplantation, Fecal microbiota Transplantation
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Hvidovre
Clostridioides Difficile Infection
Study of Clostridioides Difficile in Infants
Clostridioides difficile infection (CDI) poses an increasing threat to infant and young child health, with detection rates rising annually.
- Trial name
- NCT06788769
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Westlake University
Clostridium Difficile Infection, Fecal Microbiota Transplantation
The Dynamic Fluctuation of Donor Microbiota Affects the Prognosis of Fecal Microbiota Transplantation for C. Difficile Infection
Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the…
- Trial name
- NCT05703477
- Testing
- Fecal microbiota transplantation
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai 10th People's Hospital
Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
The primary objective of the study is to determine whether dietary intervention to increase fiber and decrease fat reduces C. difficile infection recurrence in a cohort of oncology patients.
- Conditions
- Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute, Lymphoma, Clostridium Difficile Infection
- Trial name
- NCT04940468
- Testing
- Diet Intervention
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Colorado, Denver
Clostridium Difficile Infection
A Safety Trial to Evaluate an Orally Ingested Yeast Modified to Express a Tetra-specific Anti-toxin for Clostridioides Difficile
This is a Phase 1, first-in-human, double-blind, placebo-controlled, adaptive-design, single-site study, involving dose exploration cohorts.
- Trial name
- NCT07649096
- Testing
- FZ002
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Clostridium Difficile
Influence of a New Polycationic Disinfectant on Clostridium Difficile Incidence and Environmental Colonisation
The aim of this study is to 1) test the efficacy of PHMG-based disinfectant against C. difficile spores, 2) test whether it reduces the incidence of C. difficile associated disease (CDAD) and 3) evaluate cost.
- Trial name
- NCT00566306
- Testing
- Polyhexamethyleneguanidine (PHMG)
- Volunteers
- 200 people
- Sponsor
- University of Helsinki
Diarrhea
C. Difficile and Ursodiol
In vitro findings have established that ursodeoxycholic acid is a surrogate for deoxycholic acid in preventing the growth of C. difficile, and interrupting recurrence.
- Trial name
- NCT02748616
- Testing
- Ursodiol
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- NYU Langone Health
Intestinal Infection, Clostridioides Difficile Infection
Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections
A national data registry of patients receiving the rescue fecal microbiota transplantation for the refractory intestinal infections from the China Microbiota Transplantation System was designed to assess the short-term and…
- Conditions
- Intestinal Infection, Clostridioides Difficile Infection, Antibiotic-associated Diarrhea
- Trial name
- NCT03895593
- Testing
- rescue fecal microbiota transplantation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Clostridium Difficile Infection Recurrence
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
This trial will be initiated to explore whether RBX2660 (REBYOTA®) could be suitable for administration by the practice of colonoscopy.
- Trial name
- CDI-SCOPE (NCT05831189)
- Testing
- RBX2660
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- Ferring Pharmaceuticals
Clostridium Difficile-associated Diarrhea (CDAD)
IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff
In this trial, eligible patients will be randomly assigned to receive a single dose of 400 mg/kg of IVIG or a normal saline infusion as placebo over 4-6 hours, in addition to their usual medications for CDAD.
- Trial name
- NCT00177970
- Testing
- intravenous immunoglobulin G (IVIG)
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Pittsburgh
Clostridium Difficile Infection, Clostridioides Difficile Infection
Fecal Microbiota Transplantation (FMT) for Clostridium Difficile
Faecal microbiota transplantation (FMT) is used for Clostridioides difficile infection (CDI) as part of an quality improvement initiative and conducted within the framework of Center for Faecal Microbiota Transplantation at…
- Trial name
- CEFTA (NCT03712722)
- Testing
- Faecal microbiota transplantation (FMT)
- Where
- Denmark
- Volunteers
- 2,000 people
- Sponsor
- University of Aarhus
Clostridium Difficile Infection, Prophylaxis
Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics
The purpose of this study is to determine if oral vancomycin used as primary Clostridium difficile prophylaxis can reduce the incidence of this infection in high-risk patients.
- Conditions
- Clostridium Difficile Infection, Prophylaxis, Vancomycin
- Trial name
- NCT02951702
- Testing
- Vancomycin Oral
- Volunteers
- 51 people
- Sponsor
- St. Luke's Hospital, Chesterfield, Missouri
Clostridium Difficile
Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain
The aim of this study was to analyze whether the use of the LP299v strain reduces the risk of Clostridium difficile infection (CDI) among patients receiving antibiotics and hospitalized in the nephrology and transplantation ward.
- Trial name
- NCT03368105
- Testing
- Prevention of C. difficile infections using LP299v strain
- Volunteers
- 300 people
- Sponsor
- Medical University of Silesia
Healthy Participants
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults
The purpose of this study is to measure safety, tolerability, and pharmacokinetics (PK) of a single dose of AZD5148 administered via intravenous (IV) bolus or intramuscular (IM) injection in healthy participants
- Trial name
- NCT06469151
- Testing
- AZD5148
- Where
- 4 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Clostridium Difficile Infection
Effect of Acid Suppression Medication on Pediatric Microbiome
The colonic microbiome is essential in health and disease, and is highly dynamic during the first several years of life. Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are widely used in children, but…
- Trial name
- NCT02016820
- Testing
- Omeprazole (suspension), Lifestyle Modification
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Columbia University
Diarrhea, Clostridium Difficile
Probiotics: is it Really That Good? Cost-Effectiveness of Treating the in-Patient
Medical literature has dealt with various perspectives of probiotic therapy - prevention of antibiotic associated diarrhoea, Clostridium difficile, etc.
- Trial name
- NCT00506181
- Testing
- probiotic mixture
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Hadassah Medical Organization